Volume 4 Supplement 1

Antimicrobial Resistance and Infection Control: Abstracts from the 3rd International Conference on Prevention and Infection Control (ICPIC 2015)

Open Access

N-alkyl/aralkyl-4-(3-substituted-3-phenylpropyl)piperazine-1-carbodithioate derivatives to tackle resistant trichomoniasis

  • V Bala1, 2,
  • B Kushwaha3,
  • G Gupta3 and
  • VL Sharma1
Antimicrobial Resistance and Infection Control20154(Suppl 1):P223

https://doi.org/10.1186/2047-2994-4-S1-P223

Published: 16 June 2015

Introduction

Trichomoniasis is the most common sexually transmitted infection of the urogenital tract predisposing to HIV infection and cervical cancer in women. The development of resistance against metronidazole (MTZ, the only effective approved drug for trichomoniasis), thrown a challenge to find out alternate medication.

Objectives

To Design and synthesize novel agents to be effective against MTZ resistant trichomoniasis.

Methods

Benzenepropanamines and selective serotonin reuptake inhibitor (SSRI) antidepressants viz. fluoxetine and paroxetine, possibly interacting with sulfhydryl groups present over Trichomonas.[1] Alongside dithiocarbamate nucleus is a well established pharmacophore possessing anti-Trichomonas activity.[2] In our ongoing efforts a series of benzenepropanamine-dithiocarbamate hybrids (14-28) as N-alkyl/aralkyl-4-(3-substituted-3-phenylpropyl)piperazine-1-carbodithioates have been designed, synthesized and evaluated for their anti-Trichomonas activity profile to be useful as vaginal microbicide. All compounds were tested for safety through cytotoxic assay against human cervical cell line (Hela) and compatibility with vaginal flora, Lactobacillus.

Results

2-(pyrrolidin-1-yl)ethyl 4-(3-oxo-3-phenylpropyl)piperazine-1-carbodithioate (Compound 17) was the most promising compound with anti–Trichomonas activity (MIC, 39.79 µM against MTZ susceptible and MIC, 79.92 µM against resistant strain) in comparison to MTZ (MIC, 19.71 µM against MTZ susceptible and MIC, 292.80 µM against resistant strain). Six compounds (14, 15, 17, 19, 21, 22, MIC 79.92–178.57 µM) were more active against resistant strain in comparison to Metronidazole. The extreme safety profile against vaginal epithelium (HeLa cells) and compatibility with vaginal flora (lactobacillus) supported its suitability for vaginal application.

Conclusion

A novel molecule to be effective against resistant Trichomoniasis in comparison to MTZ has been identified to be developed for topical application emphasizing on improvement of women reproductive health.

Disclosure of interest

None declared.

Authors’ Affiliations

(1)
Medicinal & Process Chemistry Division, CSIR-Central Drug Research Institute
(2)
Department of Pharmaceutical sciences, Mohan Lal Sukhadia University
(3)
Endocrinology dividion, CSIR-Central Drug Research Institute

References

  1. Kumar Kiran S.T.V.S., et al: Bioorg. Med. Chem. 2006, 14: 6593-10.1016/j.bmc.2006.06.003.View ArticlePubMedGoogle Scholar
  2. Kumar L., et al: . Eur. J. Med. Chem. 2010, 45: 817-10.1016/j.ejmech.2009.10.021.View ArticlePubMedGoogle Scholar

Copyright

© Bala et al; licensee BioMed Central Ltd. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement